CORE Biomedicine, Inc., a company focused on reimagining precision medicine through cancer lineage therapeutics, has secured $21.0M in Series A funding. The investment underscores the growing interest in highly specialized approaches to cancer treatment, particularly those that delve into the genetic origins and progression of the disease. CORE Biomedicine's work centers on developing novel therapies by understanding these intricate cancer lineages, a critical area for advancing personalized patient care.

















